Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HC&B Healthcare Communications makes appointment

This article was originally published in Scrip

Executive Summary

HC&B Healthcare Communications (US) has promoted Amy Smith from group account supervisor to account director. In her new position, she will be leading the HC&B Clinical Division, which handles medical device, pharma and biotech accounts.

You may also be interested in...



Ad Hominis: FDA Authorizes Memic Innovative’s Surgical Robot

The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.

BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A

Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.

BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle

Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel